interCLICK, Inc. (Nasdaq:ICLK) announced the appointment of Bill Wise, current CEO of MediaBank and former DoubleClick, Right Media and Yahoo executive, to its Board of Directors.

interCLICK, Inc., an audience intelligence and targeting company, engages in developing and executing data-driven campaign strategies for digital agencies and marketers.

~~~~~~~~~~~~~~~

Power3 Medical Products, Inc. (OTC.BB:PWRM) today announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for Power3’s depressed stock price and have distracted the company from its mission, Power3 plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, Power3 will continue to rigorously defend its position. For example, one such lawsuit involves Neogenomics, Inc., which was recently granted a motion for summary judgment with respect to an amount due under a convertible debenture. Power3 intends to appeal this decision.

“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger.”

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which Power3 has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which Power3 is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

~~~~~~~~~~~~~~~

GreenHouse Holdings, Inc. (OTCQB:GRHU) recently announced that it has been engaged to implement Southern California Edison’s (SCE) Automated Demand Response (Auto-DR) program for two industrial customers. The customers include Apogee Containers, Inc. and MGE UPS, LLC.

GreenHouse estimates that the projects will generate $400,000 in revenue for GreenHouse, based upon approximately 1,300 kW or 1.3 MW of electricity demand reduction and infrastructure improvements from the engagements. GreenHouse is a qualified service provider of SCE’s Auto-DR program, providing site assessment, feasibility studies, project development, engineering, and installation of enabling technologies including complete processing of all utility documents.

“Auto-DR is just one of the innovative services Greenhouse offers to help our clients implement cost effective solutions that produce positive results for all parties involved,” remarked Russ Earnshaw, President of GreenHouse. “We are truly honored to be selected by Apogee and MGE UPS and we anticipate Auto-DR being the first of many services offered in support of their energy stewardship initiatives.”

The Auto-DR program offers significant financial incentives and technical support to Southern California Edison (SCE) customers willing to install equipment that enables participation in demand response events versus depending on their employees to perform all the curtailment activities manually when required. Normally, control systems (automation) are installed with the programming needed to achieve reductions in electricity consumption during peak periods of demand on the grid.

“Participants in SCE’s Auto-DR program are in 100% control of the actual curtailment measures implemented on an event-to-event basis. By utilizing an Auto-DR system, participants will have real-time usage information and the technical means to reduce electric consumption during costly peak energy periods when the demand is highest. On-going financial benefits can be realized from program enrollment and DR event participation (benefits vary from program to program). Additionally, the systems commonly implemented for Auto-DR participation are fully capable of being used to improve productivity and equipment operating efficiencies as well as provide users with information that can augment routine and emergency operations and maintenance regimens,” adds Robert Davis, Vice President of Energy Services at GreenHouse.

GreenHouse Holdings, Inc. is a leading provider of energy efficiency solutions and sustainable infrastructure products. GreenHouse Holdings designs, engineers and installs disparate products and technologies that produce persistent technical and financial results, by enabling our clients to monitor and control their energy costs in the most efficient manner possible. GreenHouse Holdings’ target markets for energy efficiency solutions include residential, commercial and industrial, as well as government and military markets. In addition, GreenHouse Holdings develops, designs and constructs rapidly deployable, sustainable infrastructure primarily for use in disaster relief and security in austere regions.

~~~~~~~~~~~~~~~

Key Tronic Corp. (Nasdaq:KTCC) announced that it plans to report its results for the second quarter of fiscal 2011 after market close on February 1, 2011. Key Tronic will host a conference call to discuss its financial results at 2:00 PM Pacific (5:00 PM Eastern) on February 1, 2011. A broadcast of the conference call will be available at www.keytronic.com “Investor Relations” or by calling 877-941-8609 or +1 480-629-9818. A 48-hour replay will be available by calling 800-406-7325 or +1 303 590 3030 (Access Code: 4398252). A replay will also be available on the Company’s Web site.

Key Tronic Corporation, doing business as KeyTronicEMS Co., together with its subsidiaries, provides electronic manufacturing services (EMS) to original equipment manufacturers primarily in the United States, Mexico, and China.

~~~~~~~~~~~~~~~

Ocean Power Technologies, Inc (Nasdaq:OPTT) announced that it has achieved an independent certification for its utility scale PowerBuoy®, the PB150, by the internationally respected Lloyd’s Register. The certificate from Lloyd’s Register confirms that the PB150 design complies with the requirements of Lloyd’s 1999 Rules and Regulations for the Classification of Floating Offshore Installations at a Fixed Location. This provides independent, third-party assurance on the design of the PB150 PowerBuoy for its intended use, as analyzed against international standards.

Ocean Power Technologies, Inc. engages in the development and commercialization of proprietary systems that generate electricity by harnessing the renewable energy of ocean waves primarily in North America, Europe, and Australia.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received ten thousand dollars in cash and anticipates another ten thousand dollars in cash from the company for 60 days of advertisement services for Green House Holdings, Inc. (GRHU). In addition to the cash, Crown Equity Holdings Inc. (CRWE.OB) also anticipates receiving 20,000 shares of 144 restricted stocks from a third party.

Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

Worldwide, breast cancer comprises 10.4% of all cancer incidence among women, making it the most common type of non-skin cancer in women and the fifth most common cause of cancer death. In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths). Breast cancer is about 100 times more common in women than in men, although males tend to have poorer outcomes due to delays in diagnosis. Breast cancer is an uncontrolled growth of breast cells. Cancer occurs as a result of mutations, or abnormal changes, in the genes responsible for regulating the growth of cells and keeping them healthy. The genes are in each cell’s nucleus, which acts as the “control room” of each cell. Normally, the cells in our bodies replace themselves through an orderly process of cell growth: healthy new cells take over as old ones die out. But over time, mutations can “turn on” certain genes and “turn off” others in a cell. That changed cell gains the ability to keep dividing without control or order, producing more cells just like it and forming a tumor.

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 Medical Products plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3 Medical Products, with Power3 Medical Products remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

Alzheimer’s declines ultimately. Alzheimer’s is a progressing sickness, in which symptoms gradually worsen over a period of time. Continuing, memory loss is minor, but with late-stage Alzheimer’s, people will not be able to hold on a conversation and respond to their natural environment. Alzheimer’s disease is the 6th major cause of loss of life in the USA. Some people that have Alzheimer’s live life an average of eight years after their indications come to be noticeable to other people, but survival can range from 3 to 20 years, based on maturity and various health conditions. Alzheimer’s disease is among the most well known form of dementia, a broad term when it comes to forgetfulness and other intellectual abilities critical enough to obstruct everyday life. Alzheimer’s diseases is the reason for 50 to seventy per cent of dementia cases.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 Medical Products applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

—————-

American Video Teleconferencing Corp. (PINK:AVOT) is pleased to announce that it is presently in final discussions to enter into a formal agreement to acquire an exclusive option on a molybdenum property in the Otter lake area in the province of Quebec, Canada. The property has been dormant since the 1960’s when Hupon Mining and Exploration carried out surface work, stripping, trenching and a minor drill program of 445 feet contained in 11 drill holes.

Molybdenum is used in certain nickel-based alloys, such as the “Hastelloys(R)” which are heat-resistant and corrosion-resistant to chemical solutions. Molybdenum oxidizes at elevated temperatures. The metal has found recent application as electrodes for electrically heated glass furnaces and forehearths. The metal is also used in nuclear energy applications and for missile and aircraft parts. Molybdenum is valuable as a catalyst in the refining of petroleum. Molybdenum has found applications as a filament material in electronic and electrical applications. Molybdenum is an essential trace element in plant nutrition; some lands are barren for lack of this element in the soil. Molybdenum sulfide is useful as a lubricant, especially at high temperatures where oils would decompose. Almost all ultra-high strength steels with minimum yield points up to 300,000 psi (lb/in.2) contain molybdenum in amounts from 0.25 to 8%. Biologically, molybdenum as a trace element is necessary for nitrogen fixation and other metabolic processes.

Some of the sample results from the trenching in 1962 showed 0.94% to 25% molybdenum averaging 5-10%. These values were obtained from assessment files in the Department of Mines in Quebec City. This property is only one of several advanced stage properties American Video has under consideration in the province of Quebec.

The Department of Natural Resources and Wildlife is responsible for managing Québec mineral resources and oversees the consolidation and development of the mining industry to ensure that it continues to contribute to Québec’s economic development. Government management focuses first and foremost on the promotion of an innovative, competitive mining industry at the international level and its contribution to sustainable economic development. In particular, the initiatives of the Department of Natural Resources and Wildlife focus on geological and mineral exploration, the regulation of laws governing mining operations and technical, financial and scientific support for the industry. Through the support it offers for geological and mineral exploration, the department seeks to obtain and make available knowledge of the territory that pinpoints potential mining areas and to promote mining exploration in Québec. It also seeks to renew Québec mining reserves, an essential condition for ensuring the industry’s future.

—————-

Eaton Vance Municipal Income Trust (NYSE:EOT) announced the monthly distribution declared on the common shares of one of its closed-end municipal bond funds (”Funds”). The record date for the distribution is January 24, 2011, and the payable date is January 31, 2011. The ex-date is January 20, 2011. The distribution per share, closing market price on December 30, 2010 (or last trade price), and annualized market yield for the Fund. The amount of monthly distributions may vary depending on a number of factors. As portfolio and market conditions change, the rate of distributions on the Fund’s common shares could change.

—————-

Vishay Precision Group, Inc (NYSE:VPG) leading producer of sensors based on resistive foil technology and sensor-based systems, announced the Company will present at the Sidoti Semiannual Micro-Cap Conference, to be held at the Grand Hyatt Hotel in New York City, January 10, 2011. VPG’s CFO, Bill Clancy, and Sr. Mgr. IR, Mike Sheaffer, will be presenting on January 10th at 2:50pm Eastern Time. Presentation slides will be available on the Investor Relations section of the Vishay Precision Group web site: www.vishaypg.com.

Vishay Precision Group, Inc. engages in the design, manufacture, and marketing of resistive foil technology products for various applications.

—————-

Dow 30 Premium & Dividend Income Fund Inc. (NYSE:DPD) announced the quarterly distributions for two closed-end funds formerly managed by IQ Advisors as those funds change from paying distributions on a monthly basis to paying on a quarterly basis. Dow 30SM Premium & Dividend Income Fund Inc. (NYSE:DPD) and Dow 30SM Enhanced Premium & Income Fund Inc. (NYSE:DPO), have declared quarterly distributions in the amounts of $.3090 per share and $.255 per share respectively.

Dow 30 Premium & Dividend Income Fund Inc. is a close ended equity index mutual fund launched by Nuveen Investments, Inc. It is co-managed by Nuveen Asset Management and HydePark Group, LLC.

***********************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (AVOT.PK) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.

Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes Power3 is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for Power3’s depressed stock price and have distracted the company from its mission, Power3 plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc.

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

—————-

Gold Mining in Colombia, the next faze of economic development but for whom… Orofino Gold Corp. (ORFG.PK) is a China based gold producer with one producing gold mine in Colombia and an option on a strong portfolio of small producers and development/exploration assets in Colombia. Orofino Gold was founded as a private company in 2009 by former executives and management with over 50 years of combined mining exploration, finance and development experience.

Orofino’s corporate objective is to continue to build shareholder value through the exploration and development of existing projects and additional accretive acquisitions, capitalizing on the extensive experience and relationships that management has developed over the past 25 years.

Orofino Gold Corp. is a US (Nevada) company established for the purpose of creating a significant exploration and mining group to operate in Colombia. Orofino has major criteria by which they select properties that include: Significant historical production; Favorable geology for hosting major ore bodies; Significant property area for large target exploration; Recent results available; Favorable infrastructure and access to allow mine development; and Receptive local government and populace.

In addition, Orofino has acquired a database comprised of exploration and mining results from previous operators who left when the global mining sector experienced a major downturn in the three year period from 1997-2000. The second part of Orofino Gold’s strategy to become a recognized player in the Colombia mining sector was the acquisition of an interest in an operating mine. Orofino has acquired a 55% interest in the La Azul/La Estrella property with the rights to acquire up to 80%.

—————-

Scorpio Tankers Inc. (NYSE:STNG) announced that it has entered into time charter agreements for four vessels. The vessels and terms are summarized as: BW Zambesi, a 2010 built LR1 tanker (76,578 DWT), was chartered-in for one year at $13,850 per day. The vessel was delivered in December 2010. The agreement includes an option for Scorpio Tankers to extend the charter for an additional year at $14,850 per day.

Scorpio Tankers Inc. provides marine transportation of petroleum products worldwide.

—————-

Royce Micro-Cap Trust, Inc. (NYSE:RMT) the Board of Directors of Royce Micro-Cap Trust (NYSE:RMT) has approved the resumption of a quarterly distribution policy for Common Stockholders, beginning in March 2011, at the annual rate of 5%. As of December 31, 2010, the Fund had fully utilized its capital loss carryforwards for federal income tax purposes, allowing the managed distribution policy to be reinstated. The quarterly distribution policy, which was suspended by the Board in May 2009 in light of significant capital loss carryforwards, is designed to spread any capital gain distributions more evenly over the year.

Royce Micro-Cap Trust, Inc. is a closed-ended equity mutual fund launched and managed Royce & Associates, LLC.

—————-

Silvercorp Metals Inc. (NYSE:SVM) reported the results of its 2010 underground diamond drilling program at the southwest corner (also called LM Mine West) of the TLP Mining Permit area, Ying Mining District, Henan, China. This successful drill program has not only extended the existing veins to depth and along strike at the LM Mine West, but has also discovered 18 additional high grade silver (Ag) - lead (Pb) veins, increasing the total number of mineralized veins from 9 to 27.

Silvercorp Metals Inc. engages in the acquisition, exploration, development, and operation of silver mineral properties in China and Canada.

***********************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK:ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.

Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for Power3’s depressed stock price and have distracted the company from its mission, Power3 plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, Power3 will continue to rigorously defend its position.

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger.”

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

—————-

GreenHouse Holdings, Inc. (OTCQB:GRHU) revealed the results of operations for the third quarter of Fiscal Year 2010 and is providing a shareholder update. Revenues for the nine months ended September 30, 2010 were approximately $4,428,000 compared to approximately $3,486,000 for the nine months ended September 30, 2009, an increase of approximately $942,000 or 27%. This increase was due to increased sales of GreenHouse Holdings’ energy efficient products and services to residential customers as a result of GreenHouse Holdings’ expansion of GreenHouse Holdings’ sales and marketing infrastructure.

Gross profit percentage increased from 37% for the nine months ended September 30, 2009 to 41% for the nine months ended September 30, 2010 due to GreenHouse Holdings’ increased focus on negotiating better prices and discounts from GreenHouse Holdings’ suppliers and vendors, GreenHouse Holdings’ increased focus on sales training and customer pricing, and sales of higher margin products and services.

“Management is pleased with our operational and financial growth,” stated Chris Ursitti, CEO of GreenHouse Holdings. “Life Protection Inc. and the pending acquisition of Control Engineering, Inc. will provide the company with a strong foundation of growth while positioning us as a market leader within the energy efficiency and load reduction arena. In addition to expanding operations within the residential, commercial and governmental markets, we also anticipate expansion from our industrial clients as we deploy our Automated Demand Response products. We are confident that these developments will rapidly increase earnings, expand margins and allow us to achieve our ultimate goal of increased shareholder value.”

GreenHouse Holdings, Inc. is a San Diego, California based integrator of some of the world’s most innovative environmental, public safety, infrastructure technologies. GreenHouse provides systems that are financially sound and sustainable to residential, commercial, and industrial and government markets around the globe. GreenHouse provides energy-efficiency products, energy management systems, eco-friendly infrastructure, scalable waste-to-fuel bio-fuel and closed loop systems, as well as other proprietary technologies and products that are utilized to provide a greener and safer future for millions of people. Other flagship products and solutions include the Green Village, R.A.P.S., and One Link.

—————-

Chesapeake Midstream Partners, L.P. (NYSE:CHKM) announced it has agreed to acquire the Springridge natural gas gathering system and related facilities in the Haynesville Shale from Chesapeake Midstream Development, L.P., a wholly owned subsidiary of Chesapeake Energy Corporation (NYSE:CHK) (“Chesapeake”), for cash consideration of $500 million. The Partnership will acquire Chesapeake’s 100% ownership interest in the Springridge system which consists of 220 miles of gathering pipeline in Caddo and De Soto Parishes, Louisiana. The average throughput on the system during the 2010 third quarter was approximately 400 million cubic feet per day, with significant future exposure to third-party volume.

Chesapeake Midstream Partners LLC provides natural gas gathering and processing services. The company is based in the United States. Chesapeake Midstream Partners LLC operates as a subsidiary of Chesapeake Energy Corp.

—————-

Hartford Financial Services Group Inc. (NYSE:HIG) announced a definitive agreement to sell Specialty Risk Services, LLC (SRS) to Sedgwick CMS. SRS, a wholly-owned subsidiary of The Hartford, is one of the nation’s leading third-party claims administrators providing self-insured, insured, and alternative market clients with customized claims services. “The sale of SRS is consistent with our strategy to focus The Hartford on core protection and wealth management businesses,” said Liam E. McGee, The Hartford’s chairman, president and chief executive officer. “This transaction accomplishes the goal of creating shareholder value without impacting the earnings power of the company.”

The Hartford Financial Services Group, Inc., through its subsidiaries, provides insurance and financial services in the United States and internationally. The company engages in life, and property and casualty insurance businesses.

—————-

Wells Fargo & Company (NYSE:WFC) announced that area homeowners to a free home preservation workshop January 12 and 13 from 9 a.m. to 7 p.m. in Secaucus at the Meadowlands Exhibition Center for Wells Fargo Home Mortgage, Wells Fargo Financial, Wachovia Mortgage and Wells Fargo Home Equity customers facing financial hardships. Bilingual representatives will be available to assist borrowers during the event. Walk-ins are welcome, but registration is strongly recommended to guarantee customers the opportunity to meet in-person and one-on-one with a representative. For those unable to attend the Secaucus workshop on either day another will be held January 25 and 26 from 9 a.m. to 7 p.m. at the New York Marriott at Brooklyn Bridge in Brooklyn.

Wells Fargo & Company, through its subsidiaries, provides retail, commercial, and corporate banking services principally in the United States.

***********************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

Crown Equity Holdings Inc. (CRWE.OB) has received ten thousand dollars in cash and anticipates another ten thousand dollars in cash from the company for 60 days of advertisement services for Green House Holdings, Inc. (GRHU). In addition to the cash, Crown Equity Holdings Inc. (CRWE.OB) also anticipates receiving 20,000 shares of 144 restricted stocks from a third party.

Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations. Total revenues for the first quarter of fiscal 2011 increased to $25.7 million, from $25.2 million a year ago, or 2%, despite slightly lower revenues at Life Sciences resulting from a program to emphasize higher margined products, and advanced 3% sequentially. Enzo Clinical Labs benefited from an increase in market share and a new provider contract.

“We are pleased to report that our program instituted this quarter aimed at making Enzo more efficient and designed to produce more effective use of our assets is beginning to show results, as demonstrated by improved performance, ” said Barry Weiner, President of Enzo Biochem. “While we are in the early stages of this comprehensive program, the results experienced to date are very encouraging.”

Gross profit margin improved 17% to $13.5 million, or 53% of revenues, compared to the fiscal 2010 fourth quarter’s $11.5 million and was a slight improvement year over year. R&D expenses were $1.8 million, 28% lower than both a year ago and in the July 2010 quarter, and SG&A declined $0.5 million to $11.0 million, as a percentage of revenues down 3% from a year ago and 1% from the prior quarter.

Overall operating expenses, including R&D, SG&A, legal and provision for uncollectible accounts were $14.6 million, a decline of 4% from last year’s first quarter and 7% from the preceding July period. The operating loss decreased 42%, to ($1.1) million from the corresponding year-ago period, while the net loss of ($1.1) million was 38% lower year over year. EBITDA, adjusted for approximately $1.1 million in both periods for depreciation and amortization, was $23,000, compared to a year ago EBITDA loss of ($959,000), an improvement of $936,000.

Among the quarter’s highlights (all references are to sequential quarter over quarter results, normalized for an inventory charge and severance of $1.8 million where applicable): Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income; Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%; Company-wide, gross margin increased $2.0 million or 17%; Operating expenses decreased 7%, or to 57% of revenues, from 63%; EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter; and Net loss for the quarter was reduced 70%.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since Enzo Biochem’s founding in 1976, Enzo Biochem’s strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Biochem has three divisions: Life Sciences, Clinical Labs, and Therapeutics.

—————-

Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes Power3 is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few. Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

Alzheimer’s disease just isn’t an everyday aspect of increasing age, although the most significant identified risk factor is increasing age, and the most of individuals with Alzheimer’s are 65 and older. Alzheimer’s is just not a illness connected with senior years. As much as five percentage of people with the actual condition have early-onset Alzheimer’s (also called younger-onset), which frequently appears when someone is in an individual’s 40s or 50s.

Parkinson’s disease (PD) is associated with a team of disorders called motor system disorders, which are the result of the losing of dopamine-producing brain cells. Some fundamental symptoms of PD are generally tremor, or moving in hands, arms, legs, jaw, and face; hardness, or maybe tightness of the limbs and trunk; bradykinesia, or slowness of movement; and postural lack of stability, or reduced balance as well as co-ordination. Since these symptoms become more evident, patients may have challenges walking, talking, or performing many other very simple tasks.

After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. But breast cancer rates have fallen in recent years, though doctors aren’t certain why. Still, for many women, breast cancer is the disease they fear most. Breast cancer is a type of cancer where cells in the breast divide and grow without normal control. About 85 percent of breast cancers begin in the mammary ducts, while about 15 percent arise in the lobules. Tumors in the breast tend to grow slowly. By the time a lump is large enough to feel, it may have been growing for as long as 10 years. However, some tumors can be aggressive, and grow much more rapidly.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which Power3 has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which Power3 is currently engaged in Phase II clinical trials.

***********************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).